bioRxiv · 10.1101/846717
A new long-acting GLP-1 derivative 6- KTP ameliorates body weight and lipid metabolism in DIO mice
Abstract
As a global epidemic, obesity has become the biggest challenge facing global and public health. Glucagon-like peptide-1(GLP-1) has been able to inhibit appetite, slow gastric emptying and reduce body weight. We designed a novel long-acting GLP-1 derivative 6-KTP based on wild-type GLP-1 and performed its pharmacodynamics study on obesity in DIO mice. DIO mice were treated once daily with subcutaneous injections of 6-KTP (1.8 mg/kg body weight), Liraglutide (0.4 mg/kg body weight) or vehicle (phosphate buffered saline (PBS), pH 7.4) for 12 weeks. The results show that 6-KTP decreased food intake, induced anorexia and weight loss, and improved blood lipid and lipid metabolism in DIO mice.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
peixiu, w., Ran, Y.. 2019-11-18. A new long-acting GLP-1 derivative 6- KTP ameliorates body weight and lipid metabolism in DIO mice. https://doi.org/10.1101/846717
Cite the original work for its findings. Save a collection to share your selection of sources.